{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:23:41Z","timestamp":1788841421640,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Chronic kidney disease (CKD) and cancer constitute two major public health burdens, and both are on the rise. Moreover, the number of patients affected simultaneously by both conditions is growing. The potential nephrotoxic effect of cancer therapies is particularly important for patients with CKD, as they are also affected by several comorbidities. Therefore, administering the right therapy at the right dose for patients with decreased kidney function can represent a daunting challenge. We review in detail the renal toxicities of anticancer therapies, i.e. conventional chemotherapy, targeted therapy, immune checkpoint inhibitors and radioligand therapies, issue recommendations for patient monitoring along with guidance on when to withdraw treatment and suggest dosage guidelines for select agents in advanced stage CKD. Various electrolytes disturbances can occur as the result of the administration of anticancer agents in the patient with decreased kidney function. These patients are prone to developing hyponatremia, hyperkalemia and other metabolic abnormalities because of a decreased glomerular filtration rate. Therefore, all electrolytes, minerals and acid base status should be checked at baseline and before each administration of chemotherapeutic agents. Moreover, studies on patients on kidney replacement therapy are very limited and only single cases or small case series have been published. Therefore, clinical therapeutical decisions in cancer patients with decreased function should be made by multidisciplinary teams constituted of medical oncologists, nephrologists and other specialists. Onconephrology is an evolving and expanding subspecialty. It is crucial to consider anticancer drug treatment in these patients and offer them a chance to be treated effectively.<\/jats:p>","DOI":"10.1093\/ndt\/gfae142","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T01:09:20Z","timestamp":1719277760000},"page":"1976-1984","source":"Crossref","is-referenced-by-count":9,"title":["Cancer therapy in patients with reduced kidney function"],"prefix":"10.1093","volume":"39","author":[{"given":"Sabine","family":"Karam","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota , Minneapolis , MN,","place":["USA"]},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut , Beirut ,","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell H","family":"Rosner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia Health , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute, Department of Immunology and Infection , UHasselt, Diepenbeek ,","place":["Belgium"]},{"name":"Department of Nephrology, Ziekenhuis Oost Limburg , Genk ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Stec","sequence":"additional","affiliation":[{"name":"Department of Oncology, Warsaw Medical University , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2024112623572173200_bib1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"2024112623572173200_bib2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2024112623572173200_bib3","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1681\/ASN.2013060604","article-title":"CKD and the risk of incident cancer","volume":"25","author":"Lowrance","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024112623572173200_bib4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024112623572173200_bib5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00001622-199507000-00003","article-title":"Strategies to prevent nephrotoxicity of anticancer drugs","volume":"7","author":"Skinner","year":"1995","journal-title":"Curr Opin Oncol"},{"key":"2024112623572173200_bib6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s004670100658","article-title":"Ifosfamide nephrotoxicity in pediatric cancer patients","volume":"16","author":"Lee","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"2024112623572173200_bib7","first-page":"1636","article-title":"Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group","volume":"82","author":"Skinner","year":"2000","journal-title":"Br J Cancer"},{"key":"2024112623572173200_bib8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2024112623572173200_bib9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"2024112623572173200_bib10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2024112623572173200_bib11","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000001001","article-title":"Cancer drugs and acute kidney injury: new therapies and new challenges","author":"Gork","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024112623572173200_bib12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","article-title":"Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies","volume":"23","author":"Troxell","year":"2016","journal-title":"Adv Anat Pathol"},{"key":"2024112623572173200_bib13","doi-asserted-by":"publisher","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur Respir J"},{"key":"2024112623572173200_bib14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"key":"2024112623572173200_bib15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5414\/CN107921","article-title":"Pemetrexed-induced acute kidney injury leading to chronic kidney disease","volume":"82","author":"Chauvet","year":"2014","journal-title":"Clin Nephrol"},{"key":"2024112623572173200_bib16","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024112623572173200_bib17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2169\/internalmedicine.1640-23","article-title":"Renal immune-related adverse event of pembrolizumab masked by pemetrexed","volume":"63","author":"Nagase","year":"2024","journal-title":"Intern Med"},{"key":"2024112623572173200_bib18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lungcan.2022.10.007","article-title":"Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): a single-center experience","volume":"174","author":"De Giglio","year":"2022","journal-title":"Lung Cancer"},{"key":"2024112623572173200_bib19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024112623572173200_bib20","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2024112623572173200_bib21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2024112623572173200_bib22","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024112623572173200_bib23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024112623572173200_bib24","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024112623572173200_bib25","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"2024112623572173200_bib26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2024112623572173200_bib27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2024112623572173200_bib28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024112623572173200_bib29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","article-title":"Anaplastic lymphoma kinase inhibitors and their effect on the kidney","volume":"15","author":"Bonilla","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024112623572173200_bib30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/ckj\/sfad011","article-title":"Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker","volume":"16","author":"Vanhoutte","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024112623572173200_bib31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"2024112623572173200_bib32","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3390\/ijms19102902","article-title":"Renal injury during long-term crizotinib therapy","volume":"19","author":"Yasuma","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2024112623572173200_bib33","doi-asserted-by":"publisher","first-page":"101295","DOI":"10.1016\/j.tranon.2021.101295","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2022","journal-title":"Transl Oncol"},{"key":"2024112623572173200_bib34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.kint.2020.05.015","article-title":"Rondon-Berrios H. Hyponatremia in the cancer patient","volume":"98","author":"Workeneh","year":"2020","journal-title":"Kidney Int"},{"key":"2024112623572173200_bib35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","article-title":"Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management","volume":"80","author":"Oronsky","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024112623572173200_bib36","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2024112623572173200_bib37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10147-023-02307-z","article-title":"Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists","volume":"28","author":"Matsubara","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2024112623572173200_bib38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the cancer patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"key":"2024112623572173200_bib39","doi-asserted-by":"publisher","first-page":"151347","DOI":"10.1016\/j.semnephrol.2023.151347","article-title":"Hypomagnesemia in patients with cancer: the forgotten ion","volume":"42","author":"Bonilla","year":"2022","journal-title":"Semin Nephrol"},{"key":"2024112623572173200_bib40","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024112623572173200_bib41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul","year":"2021","journal-title":"Arch Osteoporos"},{"key":"2024112623572173200_bib42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024112623572173200_bib43","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor\u2013associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024112623572173200_bib44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11906-018-0864-0","article-title":"Treatment of hypertension in chronic kidney disease","volume":"20","author":"Kalaitzidis","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2024112623572173200_bib45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41371-023-00825-x","article-title":"Preexisting hypertension and cancer therapy: evidence, pathophysiology, and management recommendation","volume":"37","author":"Koskina","year":"2023","journal-title":"J Hum Hypertens"},{"key":"2024112623572173200_bib46","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024112623572173200_bib47","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy\u2013related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2024112623572173200_bib48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024112623572173200_bib49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"2024112623572173200_bib50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1188\/13.CJON.425-433","article-title":"Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer","volume":"17","author":"Grenon","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"2024112623572173200_bib51","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Failure"},{"key":"2024112623572173200_bib52","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms23052815","article-title":"Cardiotoxicity induced by protein kinase inhibitors in patients with cancer","volume":"23","author":"Grela-Wojewoda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024112623572173200_bib53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/rnj.0000000000000177","article-title":"Diagnosis and treatment of edema and lymphedema in the cancer patient","volume":"43","author":"Hutchison","year":"2018","journal-title":"Rehabil Nurs"},{"key":"2024112623572173200_bib54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1067\/mcp.2000.103973","article-title":"Pharmacokinetics of repaglinide in subjects with renal impairment","volume":"67","author":"Marbury","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"2024112623572173200_bib55","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam","volume":"20","author":"Nolin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024112623572173200_bib56","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-198510050-00003","article-title":"Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations","volume":"10","author":"Paton","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"2024112623572173200_bib57","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.kint.2019.12.023","article-title":"How to assess kidney function in oncology patients","volume":"97","author":"Malyszko","year":"2020","journal-title":"Kidney Int"},{"key":"2024112623572173200_bib58","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. US Department of Health and Human Services","year":"2017"},{"key":"2024112623572173200_bib59","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J Clin Oncol"},{"key":"2024112623572173200_bib60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","article-title":"Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function","volume":"87","author":"Mielczarek","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024112623572173200_bib61","first-page":"924","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae142\/58647352\/gfae142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/12\/1976\/60817768\/gfae142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/12\/1976\/60817768\/gfae142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:57:29Z","timestamp":1732665449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/12\/1976\/7698110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6,24]]},"published-print":{"date-parts":[[2024,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae142","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,6,24]]}}}